{"name":"Italian Trial in Medical Oncology","slug":"italian-trial-in-medical-oncology","ticker":"","exchange":"","domain":"","description":"Italian Trial in Medical Oncology (ITMO) is a clinical research organization focused on advancing oncology treatments through phase 2 trials. With a dedicated focus on infusional 5-fluorouracil, ITMO aims to improve outcomes for cancer patients.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Infusional 5-Fluorouracil","genericName":"Infusional 5-Fluorouracil","slug":"infusional-5-fluorouracil","indication":"Colorectal cancer","status":"phase_2"}]}],"pipeline":[{"name":"Infusional 5-Fluorouracil","genericName":"Infusional 5-Fluorouracil","slug":"infusional-5-fluorouracil","phase":"phase_2","mechanism":"Inhibits thymidylate synthase","indications":["Colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQndHMHhZaGl3cnhVYkVveGdXUG5nTzlQVDAtd3Jwazk0M2lnT2c1U1ptQmk1dm1ydFJ6Y3VrRWZHaFMxanFwcXRDb25LdDI2RjU3WDRIQ2RiZlozZDk0Nk1ab1ZtcWZkc1p1anlIUjJHaUYtT0hpWWpDME5uY3FQWktYT1Y1NVYydHhzYmZGM2dwd1pKUUhMV0lraHJZTDhQcjdpX1I2MXFLOUVVODQzZEtmSWlVZHBveDNIcU03M1E?oc=5","date":"2026-03-20","type":"trial","source":"Il Sole 24 ORE","summary":"Cancer, clinical trials launched in Europe halved in 10 years and China takes the scene - Il Sole 24 ORE","headline":"Cancer, clinical trials launched in Europe halved in 10 years and China takes the scene - Il Sole 24 ORE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1wWlJIeERmanhBaGR5MXllU2lsdGhKeUE3bmY4WHdKOThQeFprZk80OGIzZ1hDUGhndjFuWFd4c09LX3JkTll3VzVGN25HeU51eHpiV2tpd190VFF2UWNr?oc=5","date":"2026-01-29","type":"trial","source":"Nature","summary":"APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer - Nature","headline":"APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1kSXhQRVd0LUJWd09CR0RqRl9LczN4QkwyWE1DLWRQQ3ptdzJpRkYycGR1OWlVOTE1X3ItcFYxZXFjMFBsbzBhejFMcVZJT05lQVMzSm1jaVE0Tk11eU91dzlUNjFQaGEzdzZuM3E0cw?oc=5","date":"2026-01-28","type":"pipeline","source":"Labiotech.eu","summary":"7 biotech companies in Italy you can’t miss in 2026 - Labiotech.eu","headline":"7 biotech companies in Italy you can’t miss in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55eXBNMGx2THA3SVdXQl8xX1ZWbmZCMXBUazh6THhSamhSX0MzOVRrS3ZnRkZtZGpDMzJsbmdNQWFXbTZTdTNsZ3hDTno5YkkweDEzb0VWOGZvNUJBTVMw?oc=5","date":"2026-01-28","type":"trial","source":"Nature","summary":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial - Nature","headline":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phas","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMlEtQ056cGZpWGMwUV9qV095cUdFYm9fYzE3QkF2azFJVjNyR3V5V3h5VEZreUNaQU14VnEyR3dPNjNFUU1NOXpMWXdMNjdNcVhaWnBRZzdTd21OOGtFUGRZM0dhU1dVVWpzUWplYVpFaGlVclB4TUZmRHBqQWRIOUpCQklnbWsya3VIQ1BPeDdJQ2JvLXFhVmFCYm1OaE1ydWtRZFN5T1pOSDhRUnBCSzVpVGVlNjUy?oc=5","date":"2026-01-14","type":"trial","source":"News-Medical","summary":"Phase II clinical trial shows promising results for novel sepsis drug - News-Medical","headline":"Phase II clinical trial shows promising results for novel sepsis drug - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxORUxnaVZLVkVqM1JyNHF1ejl6c1ZkRnJrMWZsUUdCS3R4aXpSbVRZWE9la0l6NVY0UnFlYWlrczZ2Szd0dnJFMjVJdHNvc29JR2gyck5PcHZ2bWN5UldLRU9fMzk0TDUwTl9naGd4RFA4bm9LQ3phYmZGWjhHZjZyNktVUU82ck50ZkVwUmRpejlwNUxrNExQRmhmMTlqT2U5cjdRQkh5UFlpSFJPelBoVDRGcjBTZkdqcmNEQ1VCdEtYcm5KZTFxUTJFYnZsVG8yMEg3ckgxZW1wQjhXejhZLUJQcmNVeHJJb0piVEc2Z3IwTkRIS1ZoWU1IcHBOcXZZbmxySlY1QTdwdVUwQVItck5JbzVpcElEcVpldElNOW1WNGlORU5LNUstaVA?oc=5","date":"2026-01-06","type":"pipeline","source":"PR Newswire","summary":"Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 - PR Newswire","headline":"Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastroi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQeHNXNEI2VHg5bDRiTDJla05CQUxXWEZadXB2YlEwSUdLY2xSUExVMXFvZVFETWFlN3kyNHBqVUktYkhucEgxbVFtWWxCaXJkWkpDUTJMQ0hkYjhHWWY0WXZwRlVOT2dPMFBRN3ZvSi0ySmhObTRoWTduX19STFcyU3BOX1Noc1JYYjlqVVI1Yy1KVjMyTlBVYV8xSWgtMGs1MjZGRWxGMjhabkg0X1V4elV1a2VwT0t4N2VhcXdSYjRWT28wYURzUThkSlFPV0Y1NkR5QkFtM2M4aGNsLU84SDMyMnhkMG1MY3ViRVlUVQ?oc=5","date":"2025-12-09","type":"trial","source":"BioSpace","summary":"Oncology Clinical Trials Market Size Surges Toward USD 22.76 Billion as AI Transforms Recruitment and Trial Efficiency - BioSpace","headline":"Oncology Clinical Trials Market Size Surges Toward USD 22.76 Billion as AI Transforms Recruitment and Trial Efficiency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE8xWk1xaDhaaTBzalJQMFBmbDhyUlFuSjFObXFHemc2andOZ253YmdlMjNHY0hqajBNMlZGdnhMSGJaY0hYOExHcDJ6UWpmWVU3c2d5QWdLSlVsSHpUX29Ua0dHbV9iR3hDWHN1cXJNY1pVTVFh?oc=5","date":"2025-10-01","type":"trial","source":"Straits Research","summary":"Oncology Clinical Trials Market Size, Share, Players & Trends by 2034 - Straits Research","headline":"Oncology Clinical Trials Market Size, Share, Players & Trends by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9rTTl0MkNOdFdINHE5dWVvSkxZM0VpSDVMRjAteWd3aFpiSVY2RHd0bEFaalZaTHZseU1zT0RYQnZKSWtPaTR5aWJ1Yl81akgwM3VBek5tUFdsTUxG?oc=5","date":"2025-09-10","type":"trial","source":"ASCO Publications","summary":"Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity? - ASCO Publications","headline":"Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQTlBfZXNqaVhZLXlMbjVpN0NKdnJscFFGN0h4LUR4V3VDVU42ektraVdyVDZ0SUx0QkJ5ZjRDOGl5M20yWkhiNlUyQVQ1QnA0MVUxaVp2Ym8zTkNlNEVETFg2WGotRG5jYUdWZDlfT0VkclFSQzhCbEViNl82bE9hQjdsOFZEY0M5QkxTZ2J6SU0zeWZwc1J1YTl3LXhjU3JHZnRNRjdpZ2s2dmtPTEhNc3ZZaw?oc=5","date":"2025-07-29","type":"trial","source":"Fierce Pharma","summary":"Alfasigma touts results from phase 3 trial of former Galapagos JAK inhibitor Jyseleca - Fierce Pharma","headline":"Alfasigma touts results from phase 3 trial of former Galapagos JAK inhibitor Jyseleca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPTjNvX3U3elF0NlkyaEJuT0xTMEtmMHZTemdtRGdwcW9hX2JRSW82REplVFZCRlFzQ3dDeTBVU1lmNU5UZjA5U0NEdzhIT3E5ZFFhT3RJOU4taFJPR3lab3RnTWRZeUJEX0pUM2ktWWdXWVN3YmRsTkZzRTVJazVFa2xwMU12V0pvVURXdmZxTDdoUQ?oc=5","date":"2025-07-10","type":"regulatory","source":"Frontiers","summary":"The “added value” of enrolling hematological patients in clinical trials: a single-center experience - Frontiers","headline":"The “added value” of enrolling hematological patients in clinical trials: a single-center experience","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBEbm5mWDRSUDBYYXNmTC1Sb1FkQXB4dHF4ZnBzV1daZDhJLTN2VVM1blU1U3JGV3k1Wll1U2xEQjYyWG1sVEdRRkZiVTlORmFUOTFmQjVoRm1oMEVuejMzb3U0MTRNcDVSQzJNTF9qSHE3bWtDbjlvSVZOQVU?oc=5","date":"2025-07-07","type":"pipeline","source":"Cancer Therapy Advisor","summary":"Opinion: Top Studies From EHA 2025 - Cancer Therapy Advisor","headline":"Opinion: Top Studies From EHA 2025","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}